Naloxegol oxalate is a Small Molecule owned by AstraZeneca, and is involved in 27 clinical trials, which were completed.

Naloxegol is a peripherally-acting mu opioid antagonist. It antagonizes the opioid effects by competing for the same receptor sites, especially the opioid mu receptor. Opioids play an important role in chronic pain relief. They work by binding to mu-receptors in the central nervous system, but they also bind to mu-receptors in the gastrointestinal tract, which can result in patients suffering from OIC(opioid-induced constipation). Naloxegol acts on mu-receptors in the gastrointestinal tract elliciting antagonist activity, such as to provide relief from opioid-induced constipation.

The revenue for Naloxegol oxalate is expected to reach a total of $334m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Naloxegol oxalate NPV Report.

Naloxegol oxalate is currently owned by AstraZeneca. RedHill Biopharma and Kyowa Kirin are the other companies associated in development or marketing of Naloxegol oxalate.

Naloxegol oxalate Overview

Naloxegol oxalate (Movantik, Moventig, PEG-Naloxol) is an anti-constipation agent. It is formulated as pegylated film coated tablets for oral route of administration. Naloxegol is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s).

Kyowa Kirin Overview

Kyowa Kirin, a subsidiary of Kirin Holdings Co Ltd, is a biotechnology company focused on research and development. It is involved in the discovery, development, production and commercialization of pharmaceuticals and biotechnology products. The company offers drugs in the areas of nephrology, oncology, immunology and allergy, central nervous system among others. Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and others. The company operates through a network of subsidiaries in the US, Europe and Asia. Kyowa Kirin is headquartered in Tokyo, Japan.

The company reported revenues of (Yen) JPY352,246 million for the fiscal year ended December 2021 (FY2021), an increase of 10.6% over FY2020. In FY2021, the company’s operating margin was 17%, compared to an operating margin of 15.9% in FY2020. In FY2021, the company recorded a net margin of 14.9%, compared to a net margin of 14.8% in FY2020. The company reported revenues of JPY98,504 million for the third quarter ended September 2022, an increase of 1% over the previous quarter.

Quick View – Naloxegol oxalate

Report Segments
  • Innovator (NME)
Drug Name
  • Naloxegol oxalate
Administration Pathway
  • Oral
Therapeutic Areas
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.